PARR Testing in Feline Gastrointestinal Disease: When Is It Truly Helpful?
Vetopathy · Cutting Edge Diagnostics · Feline
PARR Testing in Feline Gastrointestinal Disease: When Is It Truly Helpful?
Chronic vomiting. Weight loss. Thickened intestines on ultrasound. Biopsies are submitted, and the report returns: lymphoplasmacytic enteritis, small cell lymphoma cannot be excluded. Now what?
Few areas in veterinary pathology create more clinical uncertainty than distinguishing inflammatory bowel disease (IBD) from small cell lymphoma in cats. This is often the moment when PARR testing enters the conversation. But before reaching for molecular diagnostics, it's worth stepping back. In many cases, reducing uncertainty begins with sampling depth and distribution — not PCR.
Step one: architecture still matters
Small cell lymphoma and lymphoplasmacytic enteritis can appear remarkably similar, especially in small or superficial biopsy samples. Both may show dense lymphocytic infiltrates, villous blunting, expansion of the lamina propria, and mild epitheliotropism. When biopsy samples are limited to superficial mucosa, the architectural differences that distinguish the two become difficult to evaluate.
Adequate sampling — whether deep endoscopic biopsies that include submucosa, or full-thickness surgical biopsies — allows assessment of mural infiltration, evaluation of transmural involvement, identification of architectural distortion, and, ultimately, greater diagnostic confidence. Molecular testing should not be the first solution to a sampling limitation. It is an adjunct to adequate tissue, not a substitute for it.
Distribution matters: lymphoma can be segmental
An additional challenge in feline GI disease is that small cell lymphoma can be patchy or segmental. One intestinal segment may contain diagnostic neoplastic infiltration, another region may show only inflammation, and a third site may appear nearly normal. Submitting biopsies from only one location — even if deep — may miss affected areas. Whenever feasible, sampling multiple sites, such as duodenum, jejunum, and ileum, increases the likelihood of capturing representative disease.
In cases where clinical suspicion remains high despite equivocal endoscopic biopsies, full-thickness surgical biopsies from multiple segments may significantly reduce diagnostic uncertainty. Before asking whether PARR will clarify a case, it's worth asking whether the sampling was both deep enough and broad enough.
What PARR is
PARR — PCR for Antigen Receptor Rearrangement — evaluates lymphocyte clonality by analyzing rearrangements in T-cell receptor genes and B-cell receptor (immunoglobulin) genes. In simplified terms, a polyclonal population is more consistent with inflammation, while a monoclonal population is more suggestive of lymphoma. Because lymphoma represents expansion of a single neoplastic clone, clonality testing can provide supportive evidence when histopathology falls into a gray zone.
When PARR is most helpful
PARR adds meaningful value in a few specific scenarios. The first is equivocal histopathology: even with adequate sampling, some cases remain genuinely borderline. The second is a discordant clinical picture — severe clinical signs with only mild inflammatory changes on histopathology, or progressive thickening despite appropriate IBD therapy. The third is adequate architecture with persistent uncertainty: when sampling depth and distribution are sufficient, yet morphologic overlap persists. In these situations, PARR may help tip the balance toward or away from lymphoma.
Important limitations
PARR is not a binary lymphoma test, and it carries three limitations worth keeping in mind before ordering it. False positives can occur because chronic inflammation can produce dominant clones, resulting in apparent monoclonality. False negatives can occur because early lymphoma may not yield a clearly detectable clonal population. And sampling bias remains a factor — small or limited samples may not reflect the true distribution of disease. This is exactly why sampling strategy matters so profoundly: reducing sampling error reduces reliance on molecular rescue.
Cost-benefit considerations
PARR adds expense and, at times, anxiety for clients. It is most valuable when sampling depth and distribution are already adequate, the diagnosis remains genuinely equivocal, and a treatment decision — chemotherapy, most often — hinges on clarification. It is less valuable when the primary limitation is insufficient architecture in the first place, since no amount of molecular testing corrects for tissue that wasn't representative to begin with.
Quick reference: PARR in feline GI disease
| Principle | What it means |
|---|---|
| Adequate biopsy depth | Reduces diagnostic uncertainty by allowing evaluation of submucosal and transmural architecture |
| Multiple biopsy sites | Reduces the risk of missing segmental lymphoma — sample duodenum, jejunum, and ileum when feasible |
| Architecture before molecular testing | Sampling adequacy should be assessed before PARR is ordered, not after |
| PARR supports, does not replace | Clonality testing is an adjunct to morphologic interpretation, not a substitute for it |
| Monoclonality ≠ definitive lymphoma | Chronic inflammation can produce a dominant clone and a false-positive result |
| Polyclonality ≠ definitive inflammation | Early lymphoma may not yield a detectable clonal population — a false negative |
Distinguishing small cell lymphoma from inflammatory enteropathy remains one of the more nuanced areas of feline pathology. The most reliable path to clarity involves thoughtful sampling, adequate depth, multi-site distribution, careful morphologic interpretation, and targeted molecular support when it's actually going to move the needle.
Eric Snook, DVM, PhD, DACVP — Vetopathy. If you're debating whether additional sampling or PARR testing would meaningfully clarify a specific case, I'm always happy to review findings and discuss strategy before proceeding.